Table 9.
Relative cell survivals after consecutive treatments with the nanobodies, in comparison with consecutive treatments with temozolomide.
| Consecutive nanobody pairs | U251MG |
U87MG |
NCH644 |
NCH421k |
Astrocytes |
|||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sign. | p-value | Sign. | p-value | Sign. | p-value | Sign. | p-value | Sign. | p-value | |
| Nb79+Nb79 | * | 0.0229 | **** | 0.0001 | **** | 0.0001 | ** | 0.005 | *** | 0.0003 |
| Nb179+Nb179 | ** | 0.0023 | **** | 0.0001 | ** | 0.0031 | ns | 0.9699 | **** | 0.0001 |
| Nb225+Nb225 | ** | 0.0047 | **** | 0.0001 | **** | 0.0001 | *** | 0.0007 | **** | 0.0001 |
| Nb314+Nb314 | *** | 0.0001 | **** | 0.0001 | * | 0.0337 | ns | 0.2453 | **** | 0.0001 |
| Nb79+Nb179 | *** | 0.0007 | **** | 0.0001 | * | 0.0246 | ns | 0.968 | **** | 0.0001 |
| Nb179+Nb225 | ** | 0.0034 | **** | 0.0001 | **** | 0.0001 | ns | 0.9998 | **** | 0.0001 |
| Nb225+Nb314 | * | 0.0308 | **** | 0.0001 | **** | 0.0001 | ns | 0.9999 | **** | 0.0001 |
Significances of three samples with three replicates were calculated by one-way ANOVA. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns, not significant.
ANOVA, analysis of variance; Sign., significance.